1172-76 Healthcare costs for cardiovascular disease in women with and without obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institutes-Sponsored Women's Ischemia Syndrome evaluation (WISE)

Shaw, Leslee J.; Sharaf, Barry L.; Johnson, Betty D.; Sopko, George; Pepine, Carl J.; Pohost, G. M.; Reis, Steven E.; Rogers, William; Kelsey, Sheryl F.; Merz, C.Noel Bairey

doi:10.1016/s0735-1097(04)91781-0

Search citation statements

Order By: Relevance

Paper Sections

Select...

Why the Difference?1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2006

Publication Types

Select...

Article2

Relationship

Self Cite2

Independent0

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another presentation will summarize the estimated lifetime cost of care for cardiovascular disease by the angiographic extent of disease (7). Even women with no disease by angiography have in excess of $750,000 for lifetime costs for care.…”

Section: Why the Difference?mentioning

confidence: 99%

Ischemic heart disease in women: facts and wishful thinking

Pepine

2004

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Why the Difference?mentioning

confidence: 99%

Ischemic heart disease in women: facts and wishful thinking

Pepine

2004

Journal of the American College of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study

Shaw

Merz

Pepine

et al. 2006

Journal of the American College of Cardiology

Self Cite

633

182

View full text Add to dashboard Cite

Despite a dramatic decline in mortality over the past three decades, coronary heart disease is the leading cause of death and disability in the U.S. Importantly, recent advances in the field of cardiovascular medicine have not led to significant declines in case fatality rates for women when compared to the dramatic declines realized for men. The current review highlights gender-specific issues in ischemic heart disease presentation, evaluation, and outcomes with a special focus on the results published from the National Institutes of Health-National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. We will present recent evidence on traditional and novel risk markers (e.g., high sensitivity C-reactive protein) as well as gender-specific differences in symptoms and diagnostic approaches. An overview of currently available diagnostic test evidence (including exercise electrocardiography and stress echocardiography and single-photon emission computed tomographic imaging) in symptomatic women will be presented as well as data using innovative imaging techniques such as magnetic resonance subendocardial perfusion, and spectroscopic imaging will also be discussed.

show abstract

1172-76 Healthcare costs for cardiovascular disease in women with and without obstructive coronary disease: Results from the National Institutes of Health-National Heart, Lung, and Blood Institutes-Sponsored Women's Ischemia Syndrome evaluation (WISE)

Cited by 2 publications

References 0 publications

Ischemic heart disease in women: facts and wishful thinking

Ischemic heart disease in women: facts and wishful thinking

Insights From the NHLBI-Sponsored Women’s Ischemia Syndrome Evaluation (WISE) Study

Contact Info

Product

Resources

About